Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Low-Density Lipoprotein Test Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
The report unveils the market's progression from a value of $8.11 billion in 2023 to an anticipated $10.24 billion by 2028, advancing at a compound annual growth rate (CAGR) of 4.9%. The historical and forecast data sheds light on the burgeoning necessity for LDL testing emanating from escalating cardiovascular disease prevalence and heightened awareness surrounding heart health.
Regional Growth Highlights and Notable Trends
Nurturing its position as the largest market, North America continues to dominate the LDL Test landscape, with advancements in cardiovascular research and health policies strongly influencing the North American market. Simultaneously, Asia-Pacific, Western Europe, and other populous regions feature prominently in the report, embodying significant potential for market expansion.
Key trends emerging in the forecast period include the development and adoption of new, ground-breaking medication and therapies that target LDL cholesterol levels, as well as technologically advanced diagnostic methods that streamline and enhance LDL testing protocols.
Innovations in the LDL Test Market
Our analysis highlights critical product innovations from major market players, which are setting new standards for efficacy and convenience in LDL cholesterol management. The emergence of homogenous assays and novel therapeutic options represent key advancements poised to propel the market forward.
Expanding Applications of LDL Testing
LDL tests, including varied types such as LDL-C, LDL-P, LDL-B, and others, are crucial for managing a spectrum of health conditions ranging from diabetes and obesity to peripheral arterial disease and angina. The report showcases the diverse components - kits, reagents, devices - used across these applications, embedding LDL tests within an expansive healthcare landscape.
With the increase in demand for LDL tests, the report also addresses diverse distribution channels and settings such as hospitals, clinics, ambulatory care centers, and research laboratories, providing a holistic view of the market's extensive reach and potential.
Comprehensive Market Insights
The supplied narrative offers an in-depth market evaluation, including comprehensive regional analyses, market shares, and competitive landscapes. The research underscores the significance of the LDL test market's role in public health, with its substantial reach and influence across the healthcare industry.
A selection of companies mentioned in this report includes
- Abbott Laboratories
- Qiagen N.V.
- Randox Laboratories Ltd.
- Eurofins Scientific SE
- Danaher Corporation
- Bio-Rad Laboratories Inc.
- OPKO Health Inc.
- Lincoln Diagnostics LLC
- DiaSorin S.p.A.
- Boster Biological Technology Ltd.
- Rockland Immunochemicals Inc.
- Sekisui Diagnostics LLC
- DiaSys Diagnostic Systems GmbH
- Eurolyser Diagnostica GmbH
- Diazyme Laboratories Inc.
- Cell Biolabs Inc
- Home Access Health Corporation
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company
- Quest Diagnostics Incorporated
- SpectraCell Laboratories Inc.
- Siemens AG
- Alfa Wassermann Inc.
- Laboratory Corporation of America Holdings
- Merck KGaA
- F Hoffmann-La Roche Ltd.
- Agilent Technologies Inc.
- BioVision Incorporated
- Abcam plc
- BioAssay Systems
- BioChain Institute Inc.
- BioLegend Inc.
- Bioo Scientific LLC
- Enzo Life Sciences Inc.
- GenScript Biotech Corporation
For more information about this report visit https://www.researchandmarkets.com/r/lzgzd5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
